Influenza is a highly contagious respiratory illness that affects millions of people worldwide each year. The influenza virus is constantly evolving, making it difficult to predict and prevent outbreaks. Current influenza vaccines come in various types, including live attenuated virus vaccines, inactivated whole virus vaccines, virosome vaccines, split-virion vaccines, and subunit vaccines.
However, they have certain limitations, such as high manufacturing costs, prolonged production time, moderate effectiveness among specific groups, and limited cross-reactivity.
About this webinar:
This webinar outlines recent advancements in the development and use of different types of influenza vaccines, as well as future directions, such as creating universal influenza vaccines.
Furthermore, the immune response is a critical factor in evaluating the vaccine's efficacy and side effects, and it is measured by detecting cytokines such as IFN-α, IL-6, and G-CSF. The association between cytokine production and influenza vaccine antibody response will also be discussed. Sino Biological offers the world's largest collection of influenza bioreagents to support influenza research.
Key Learning Objectives:
- Overview of the impact of Influenza A and B viruses on global health
- Current strategies and recent advances in the development and application of influenza vaccines
- Cytokine release in response to influenza vaccine
- Challenges and future directions for influenza vaccine research and development
About the webinar speaker:
Dr. Mohammad Safiarian is the Associate Product Manager at SinoBiological, where he is responsible for product development and marketing of protein products. He earned his Ph.D. in Biochemistry from Georgia State University and completed post-doctoral training at the Georgia Institute of Technology and Baylor College of Medicine.
Dr. Safiarian's expertise lies in protein science, DNA biochemistry, and enzymology, and he has authored several peer-reviewed papers with over 100 citations.